Sarcomatrix Therapeutics selected as BIO Start-Up Stadium finalist

Sarcomatrix Therapeutics has been named a Seed-Stage Finalist for BIO International Convention’s Start-Up Stadium 2026 in San Diego, giving the Reno biotech a platform to pitch investors and partners as it works toward an expected IND filing later this year. Why it matters: - Sarcomatrix Therapeutics gets a high-profile stage at BIO International Convention, where early biotech companies can meet global investors and strategic partners. - The recognition comes as the company pushes its lead programs toward a planned IND submission in the fourth quarter of 2026. - The company is developing therapies for rare neuromuscular diseases with limited treatment options. What happened: - Sarcomatrix Therapeutics was selected as a Seed-Stage Finalist in the Start-Up Stadium competition at the 2026 BIO International Convention. - The convention runs June 21-24 in San Diego. - Sarcomatrix will present its pipeline and corporate strategy on Tuesday, June 23, 2026, from 2:00-4:00 PM PT in Room 5B. - Start-Up Stadium is BIO’s flagship showcase for emerging biotechnology companies. - The event connects selected companies with venture capital firms, strategic pharmaceutical partners and venture philanthropy organizations. The details: - Sarcomatrix is developing a pipeline for severe neuromuscular disorders. - S-969 is a first-in-class, oral, mutation-agnostic small molecule in development for Duchenne muscular dystrophy, Becker muscular dystrophy and limb-girdle muscular dystrophy type 2I/R9. - An application for U.S. Orphan Drug Designation for S-969 is in preparation. - LAM-111 is a recombinant human laminin-111 therapy in development for LAMA2-related congenital muscular dystrophy. - LAM-111 has Orphan Drug Designation in the United States and European Union. - SarcoVista™ is the company’s AI-enabled translational platform for target identification, biomarker discovery and program development. - Sarcomatrix was spun out of the Burkin Laboratory at the University of Nevada, Reno. - The company’s foundational technology was licensed through the Nevada Center for Applied Research. - Sarcomatrix is headquartered in Reno, Nevada. - David Craig is president and CEO of Sarcomatrix Therapeutics. - Craig holds a B.S. in Pharmacy from South Dakota State University and an MBA from Pepperdine University’s Graziadio Business School. - Craig is also the author of The New Rules of Biotech: A Founder’s Guide to Building Great Companies. - More information is available at the company’s announcement . Between the lines: - The finalist selection signals external validation for a company still in the preclinical-to-clinical scaling phase. - BIO exposure can help smaller biotech firms sharpen fundraising, business development and partnering conversations. - The company’s mix of a mutation-agnostic small molecule, a biologic therapy and an AI-enabled platform suggests a broad approach to rare disease drug development. - The stated IND timeline and orphan drug milestones point to a near-term regulatory focus, but those plans remain forward-looking. What’s next: - Sarcomatrix will present at Start-Up Stadium during BIO International Convention on June 23. - The company is working toward an IND submission for its lead candidate in Q4 2026. - Development progress on S-969, LAM-111 and SarcoVista™ will likely shape future partnering and financing discussions. - Forward-looking statements in the release note that development timelines, regulatory filings and clinical activities remain subject to biotechnology, regulatory and financing risks.